Fundraising FoxFrazier Life Sciences — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization.
AI & Machine LearningBiotechSouth San Francisco, US
Charles Homcy(Director)Jason Coloma(Chief Executive Officer)in
Co-investorsAndreessen HorowitzARCH Venture PartnersForesite CapitalGV (Google Ventures)Hercules Capital, Inc.Alexandria+9 more
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in
BoardMarcos Milla(Director)inJay Lichter(Director)inTighe Reardon(Executive Officer)
Board seatJames Topper· per SEC Form D
Co-investorsLightspeed Venture PartnersSamsara BioCapitalAvalon BioVenturesPappas CapitalPfizer Venture InvestmentsJ.P. Morgan Asset Management+1 more
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Co-investorsOrbiMedRA CapitalSanofi VenturesSofinnova VenturesViking GlobalAgent Capital+11 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.